EUVIMEDEUVIMED entdecken
Crossref

Protein Kinase C Beta II Expression in Diffuse Large B-Cell Lymphoma Predicts for Inferior Outcome of Anthracycline-Based Chemotherapy With And Without Rituximab

Harshal Nandurkar, Kritika Chaiwatanatorn, Georgia Stamaratis, Kenneth Opeskin, Frank Firkin

Clinical Lymphoma and Myeloma · 2009-12 · 9 (6) · E31

DOI: 10.3816/clm.2009.n.093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma and Myeloma, 2009-12. Verfasst von Harshal Nandurkar und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Nandurkar, H., Chaiwatanatorn, K., Stamaratis, G., Opeskin, K., & Firkin, F. (2009). Protein Kinase C Beta II Expression in Diffuse Large B-Cell Lymphoma Predicts for Inferior Outcome of Anthracycline-Based Chemotherapy With And Without Rituximab. Clinical Lymphoma and Myeloma, 9(6), E31. https://doi.org/10.3816/clm.2009.n.093

Vancouver

Nandurkar H, Chaiwatanatorn K, Stamaratis G, Opeskin K, Firkin F. Protein Kinase C Beta II Expression in Diffuse Large B-Cell Lymphoma Predicts for Inferior Outcome of Anthracycline-Based Chemotherapy With And Without Rituximab. Clinical Lymphoma and Myeloma. 2009;9(6):E31. doi:10.3816/clm.2009.n.093

BibTeX
@article{Nandurkar2009,
  author = {Nandurkar, Harshal and Chaiwatanatorn, Kritika and Stamaratis, Georgia and Opeskin, Kenneth and Firkin, Frank},
  title = {Protein Kinase C Beta II Expression in Diffuse Large B-Cell Lymphoma Predicts for Inferior Outcome of Anthracycline-Based Chemotherapy With And Without Rituximab},
  journal = {Clinical Lymphoma and Myeloma},
  year = {2009},
  volume = {9},
  number = {6},
  pages = {E31},
  doi = {10.3816/clm.2009.n.093}
}
Kostenlos starten →